A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
Sponsor: Immune Oncology Network (ION)
Listed as NCT04144517, this PHASE2 trial focuses on Squamous Cell Carcinoma of Head and Neck and remains completed. Sponsored by Immune Oncology Network (ION), it has been updated 14 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Feb 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Nov 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Sep 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Immune Oncology Network (ION)
- Mural Oncology, Inc
For direct contact, visit the study record on ClinicalTrials.gov .